Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)

Ghent University Hospital (UZ)

Status and phase: Completed; Phase 4

Conditions: Vitiligo

Treatments: Drug: local mometasone furoate treatment; Drug: topical tacrolimus treatment; Drug: topical pimecrolimus treatment; Drug: cold cream

Study type: Interventional

Funder types: Other

Identifiers

NCT01082393

2009/599

Details and patient eligibility

About

We will investigate the process of vitiligo induction and the influence of different commonly used cream treatments on this process. Studies comparing different treatments for vitiligo in the induction stage of the disease are still missing. The study hypothesis = cream treatment can stop actively spreading vitiligo lesions during the early induction stage of the disease.

Enrollment: 14 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female,
• Age 18-70 years,
• Extensive vitiligo (> 50% body surface area),
• Patients asking for depigmenting therapy,
• Not pregnant.

Exclusion criteria

• Children,
• Non extensive vitiligo (< 50% boy surface area),
• Patients not asking for depigmenting therapies,
• Pregnant.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

14 participants in 4 patient groups, including a placebo group

topical tacrolimus

Active Comparator group

Treatment:

Drug: topical tacrolimus treatment

topical pimecrolimus

Active Comparator group

Treatment:

Drug: topical pimecrolimus treatment

local steroids

Active Comparator group

Treatment:

Drug: local mometasone furoate treatment

cold cream

Placebo Comparator group

Treatment:

Drug: cold cream